Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.72 |
| ▸ | MAPK7 | Q13164 | 12/20 | 0.72 |
| ▸ | DCLK1 | O15075 | 11/20 | 0.72 |
| ▸ | BRD4 | O60885 | 9/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18369845 | 0.84 | MAPK7 (0.54) | LRRK2MAPK7DCLK1BRD4KCNH2 | |
| SCHEMBL20094404 | 0.84 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4GAK | |
| SCHEMBL18370051 | 0.77 | BRD4 (0.68) | LRRK2MAPK7DCLK1BRD4KCNH2 | |
| SCHEMBL20094173 | 0.77 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4GAK | |
| SCHEMBL31092850 | 0.77 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4GAK | |
| SCHEMBL20094143 | 0.77 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4GAK | |
| SCHEMBL18369869 | 0.77 | PRKDC (0.53) | MAPK7BRD4KCNH2MTOR | |
| SCHEMBL18369841 | 0.77 | MAPK7 (0.61) | LRRK2MAPK7DCLK1BRD4KCNH2 | |
| SCHEMBL18369861 | 0.76 | MAPK7 (0.53) | LRRK2MAPK7DCLK1BRD4KCNH2 | |
| SCHEMBL18369843 | 0.76 | MAPK7 (0.52) | LRRK2MAPK7DCLK1BRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | LRRK2 525/4885MAPK7 58/4885DCLK1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.